NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q3 2025 vs. Q2 2025
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 17 | 10 | −7 |
| Shares | 510.0K | 277.9K | −232.1K (−45.5%) |
| Value | $964.4K | $346.8K | −$617.6K (−64.0%) |
New holders (1)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Investments, LP | 21,086 | $26.4K | 0.00% |
Sold out (8)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Citadel Advisors LLC | 149,243 | $282.1K |
| Yorkville Advisors Global, LP | 60,000 | $113.4K |
| Jane Street Group, LLC | 28,689 | $54.2K |
| HRT Financial LP | 21,694 | $41.0K |
| Marshall Wace, LLP | 11,828 | $22.4K |
| BNP Paribas Arbitrage, SA | 6,800 | $12.9K |
| Hurley Capital, LLC | 6,530 | $12.3K |
| Total Investment Management Inc | 500 | $945 |